aTYR PHARMA (ATYR) Short-term Investments (2014 - 2026)

aTYR PHARMA (ATYR) has 13 years of Short-term Investments data on file, last reported at $56.5 million in Q1 2026.

• Quarterly Short-term Investments fell 14.37% year-over-year to $56.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.5 million (down 14.37% YoY) and the FY2025 annual result came in at $67.9 million, up 11.26% from the prior year.
• Short-term Investments fell to $56.5 million in Q1 2026, from $67.9 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $96.3 million in Q2 2023 to a low of $54.5 million in Q3 2024.
• A 5-year average of $73.3 million and a median of $71.7 million in 2024 frame the typical range for Short-term Investments.
• The widest YoY moves for Short-term Investments: up 137.43% in 2022, down 46.8% in 2022.
• Tracing ATYR's Short-term Investments over 5 years: stood at $56.2 million in 2022, then surged by 34.64% to $75.6 million in 2023, then retreated by 19.24% to $61.1 million in 2024, then climbed by 11.26% to $67.9 million in 2025, then declined by 16.84% to $56.5 million in 2026.
• The last three Short-term Investments figures came in at $56.5 million (Q1 2026), $67.9 million (Q4 2025), and $84.1 million (Q3 2025), per Business Quant data.